Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Jasper Therapeutics Inc

JSPR ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.72

▲ +0.89%

Market Cap $24.04M · Vol 76.47K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$24.04M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+62.06%

YoY

RSI (14)

54.17

Momentum

Beta

3.03

vs Market

52W High

$2.98

75.76% below

52W Low

$0.32

126.81% above

Volume

76.47K

Avg 261.32K

P/B

12.34

Price-to-book

ROE

-230.31%

Return on equity

Free Float

97.44%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Jasper Therapeutics Inc (JSPR) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does JSPR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-14.22%

+4.94%

-20.00%

-47.65%

YTD

-60.52%

-75.34%

-94.49%

-99.27%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-75,801,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-230.31%
ROA · ROIC	-131.06% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	12.34
P/FCF	N/A
EPS Growth	+62.06%
Outstanding Shares	33.27M

Technical Indicators

50-Day SMA	$0.63
200-Day SMA	$1.13
RSI (14)	54.17
Beta	3.03
52-Week High	$2.98
52-Week Low	$0.32

Volume Today	76.47K
Avg Daily Volume (30D)	261.32K
Relative Volume	0.29x
Volatility (10D)	114.61
Volatility (30D)	121.23
Free Float	97.44%

Analyst Consensus

BUY

Current Price $0.72

Mean Target $7.30

52W Low$0.32 52W High$2.98

Current

Target

$0.32 $2.98

Current Analyst target

+910.52% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00QPZNPB4

ISINUS4718712023

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -3.94% ARGX.BR argenx SE -4.19% ARGX argenx SE -2.76% INSM Insmed Inc -1.42% 2269.HK WuXi Biologics (Cayman) Inc -4.71%

Company Profile

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.